Lantern Pharma Inc. reported its financial results for the first quarter of 2026, revealing a net loss of approximately $3.33 million, a decrease from a net loss of about $4.54 million in the same period of 2025. The company's total operating expenses for the quarter were approximately $3.41 million, down from $4.77 million year-over-year. This reduction in losses is attributed to a significant decrease in research and development expenses, which fell by 47% to approximately $1.72 million, compared to $3.26 million in the prior year. General and administrative expenses also increased by 11% to approximately $1.68 million, primarily due to higher patent costs and salaries.
In terms of liquidity, Lantern Pharma reported total assets of approximately $7.22 million as of March 31, 2026, down from $11.04 million at the end of 2025. The company had cash and cash equivalents of approximately $4.92 million, an increase from $4.42 million at the end of the previous fiscal year. However, marketable securities saw a significant decline, dropping to approximately $1.41 million from $5.70 million. The company’s working capital stood at approximately $3.28 million, indicating a need for additional funding to support ongoing operations and clinical trials.
Strategically, Lantern Pharma is advancing its drug development pipeline, which includes three clinical-stage oncology candidates: LP-300, LP-184, and LP-284. The company has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus on the development of LP-184 for central nervous system cancers. Additionally, Lantern Pharma announced plans to create an independent business entity for its AI platform, withZeta.ai, to enhance funding opportunities and potentially increase its market valuation. This initiative is expected to separate the AI assets from the primary drug development operations.
The company continues to face challenges in securing sufficient funding for its operations. Lantern Pharma has indicated that it will need substantial additional capital to fund its ongoing research and development activities beyond mid-2027. The recent registered direct offering, which closed on May 14, 2026, raised approximately $4.4 million, but the company has expressed concerns about its ability to continue as a going concern without further capital raises. The filing highlights the importance of ongoing capital management and the potential impact of market conditions on future funding efforts.
Looking ahead, Lantern Pharma remains focused on leveraging its RADR® platform to identify and develop drug candidates that can address unmet medical needs in oncology. The company aims to continue its clinical trials and expand its portfolio while navigating the complexities of funding and market dynamics. The outlook remains cautious, with the acknowledgment that the company may need to adjust its strategies based on the availability of capital and the progress of its drug development programs.
About Lantern Pharma Inc.
Lantern Pharma Inc. is an AI-driven biopharmaceutical company focused on developing targeted cancer therapies. Its proprietary RADR platform analyzes vast genomic and clinical data to identify and rescue promising drug candidates, including small molecules and antibody-drug conjugates. The company targets oncology markets with personalized, biomarker-driven treatments, leveraging data science to accelerate drug discovery, reduce costs, and improve patient outcomes in solid tumors and blood cancers.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.